Ocular Therapeutix

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI, expected to close randomization in early December 2024. SOL-1 is the first registrational trial for wet AMD, with topline data anticipated in Q4 2025. The momentum from SOL-1 has accelerated enrollment in the SOL-R repeat dosing trial, with Ocular Therapeutix activating additional sites worldwide.

Over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI, with randomization expected to close in early December 2024. This is the first registrational trial for OTX-TKI in wet AMD, with topline data anticipated in Q4 2025. The momentum from SOL-1 has accelerated enrollment in Ocular’s second registrational trial, SOL-R, which now allows direct enrollment from SOL-1.

Switch Market flag for targeted data from your country of choice. Right-click on the chart for more options. Use up/down arrows to navigate symbols.

Ocular Therapeutix announces over 300 patients randomized in SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline data expected in Q4 2025. Active sites enroll patients into second registrational trial, SOL-R, accelerating its enrollment. SOL-1 and SOL-R aim to provide durable, repeatable, and flexible dosing options for wet AMD patients.

DelveInsight's report on the Acute Ocular Pain Market forecasts significant growth (2020-2034) in the US, EU4, UK, and Japan. Key companies include Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma, Ocular Therapeutix, Kala Pharmaceuticals, and Bausch & Lomb. Recent FDA approvals and ongoing research are driving market dynamics, with treatments like DEXTENZA, INVELTYS, and LOTEMAX SM addressing post-operative pain. The market is expected to surge due to increasing prevalence and pipeline product launches.

Scotiabank identifies Rocket Pharmaceuticals, Liquidia Corp, and Ocular Therapeutix as top biotech picks, predicting over 100% stock growth in 12 months due to anticipated macroeconomic changes and strong sector execution.

Ocular Therapeutix's Pravin U. Dugel, MD, discusses the next steps for phase 3 SOL-1 and SOL-R studies investigating Axpaxli for wet age-related macular degeneration.

FDA approves Bausch + Lomb's enVista Envy IOL, offering continuous vision and dysphotopsia tolerance. Rising diabetic retinopathy rates in youth signal a public health crisis. Myopia management transitions from a specialty to primary care. Ocular drug delivery for dry eye focuses on inflammation modulation. Ocular Therapeutix accelerates SOL-1 Phase 3 trial for wet AMD treatment.